Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and LowRisk Smoldering Multiple Myeloma

Omar Nadeem,Robert A. Redd,Michael Z. Koontz,Jeffrey V. Matous,Andrew J. Yee,Jeffrey A. Zonder,Andrew Kin,Jacalyn Rosenblatt,Julia Prescott,Kelsey Tague,Veronica Romines,Meredith Bertoni,Amada Metivier,Rebekah Medina,Alexandra Savell,Houry Leblebjian,Alexandra Distaso,Clifton C. Mo,Jacob P. Laubach,Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial

BLOOD（2021）

Cited 2|Views18
No score
Abstract
Introduction : Daratumumab (Dara) is an anti-CD38 monoclonal antibody that is approved for use in patients with newly diagnosed and relapsed multiple myeloma (MM). We hypothesized that early therapeutic intervention with Dara in patients with high-risk MGUS (HR-MGUS) or low-risk SMM (LR-SMM) would lead to eradication of the tumor clone by achieving deep responses, resulting in prevention of progression to MM. We present results of our phase II, single arm study of Dara in HR-MGUS and LR-SMM.
More
Translated text
Key words
daratumumab,high-risk,low-risk
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined